Eastgate Biotech Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETBI research report →
Price Chart
About the company
EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body.
- CEO
- Rosella C. Perri
- IPO
- 2014
- Employees
- 2
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on ETBI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.29M
- P/E
- -2.63
- PEG
- -0.38
- P/S
- 103.15
- P/B
- -0.98
- EV/EBITDA
- -4.77
- Div Yield
- 0.00%
- Gross Margin
- -110.37%
- Op Margin
- -3282.39%
- Net Margin
- -3553.67%
- ROE
- 40.71%
- ROIC
- 63.23%
Latest fiscal year · YoY change
- Revenue
- $99.73K-26.7%
- Gross Profit
- $-110,079-59.8%
- Op Income
- $-3,273,690
- Net Income
- $-3,544,249-136.6%
- EPS
- $-0.00-58.3%
- OCF Growth
- +144.1%
- FCF Growth
- +123.3%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.42
- RSI (14)
- 65
- Avg Volume
- 2.72K
No earnings-call transcripts are available for ETBI yet.
- Free Float
- 72.6%
- Shares Outstanding
- 2.06B
- Float Shares
- 1.49B
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 15, 15 | PERRI ROSE C | other | 0 |
| Jan 15, 15 | PERRI ROSE C | other | 0 |
| Jan 5, 15 | PERRI ROSE C | other | 1,036,475 |
| Nov 9, 14 | PERRI ROSE C | other | 320,400 |
| Jan 5, 15 | GLUSKIN ANNA E | buy | 1,243,750 |
| Jan 5, 15 | GLUSKIN ANNA E | buy | 1,243,750 |
| May 22, 12 | SCHWARZ JOSEPH | other | 0 |
| May 22, 12 | WEISSPAPIR MICHAEL | other | 0 |
| May 22, 12 | Hasanagic Mirjana Mira | other | 0 |
| May 22, 12 | Lukian Brian | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ETBI coverage
Recent articles, reports, and earnings notes.
No research on ETBI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ETBI report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.